Favorable response to second-line atezolizumab and bevacizumab following progression on nivolumab in advanced hepatocellular carcinoma: A case report demonstrating that anti-VEGF therapy overcomes resistance to checkpoint inhibition.

Medicine (Baltimore) · 2021 · PMC8238293 · PMID 34160456

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

[ 8 ] Similarly, the PD-1 inhibitor pembrolizumab was shown to be safe and effective in previously treated patients with advanced HCC, although, as observed with nivolumab, survival benefit did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.